{"prompt": "['PREDM', 'Page 1', 'St. Jude', 'PREDM', 'Initial version, dated: 04-10-2020, (IRB Approved: 00-00-00)', 'Activation Date: 00-00-00', 'PREDM: AN OPEN-LABEL PILOT INTERVENTION TRIAL TO PREVENT DIABETES IN', 'PREDIABETIC ADULT SURVIVORS OF CHILDHOOD CANCER', 'IND/IDE # (if applicable)', 'Principal Investigator', 'Stephanie B. Dixon, MD, MPH', 'Department of Oncology, Division of Cancer Survivorship', 'Collaborating Co-Investigators', 'Gregory T. Armstrong, MD, MSCE', 'Department of Epidemiology and Cancer Control', 'Tara M. Brinkman, PhD', 'Department of Epidemiology ad Cancer Control', 'Wassim Chemaitilly, MD', 'Department of Pediatrics, Division of Endocrinology', 'Matthew J. Ehrhardt, MD, MS', 'Department of Oncology, Division of Cancer Survivorship', 'Timothy E. Folse, MD', 'Department of Oncology, Division of Cancer Survivorship', 'Thomas E. Merchant, DO, PhD', 'Department of Radiation Oncology', 'Daniel A. Mulrooney, MD, MS', 'Department of Oncology, Division of Cancer Survivorship', 'Sedigheh Mirzaei Salehabadi, PhD', 'Department of Biostatistics', 'Kirsten K. Ness, PhD', 'Department of Epidemiology and Cancer Control', 'DeoKumar Srivastava, PhD', 'Department of Biostatistics', 'Melissa M. Hudson, MD', 'Department of Oncology, Director, Division of Cancer Survivorship', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date NUMBER: 00-00-00 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 2', 'Leslie L Robison, PhD', 'Chair, Department of Epidemiology and Cancer Control', \"St. Jude Children's Research Hospital\", '262 Danny Thomas Place', 'Memphis, Tennessee 38105-3678', 'Telephone: (901) 595-3300', 'Contents of this document may not be extracted without permission from the Principal Investigator.', 'Initial version, dated: 04-10-20', 'IRB approkB', \"St. Jude date Children's Research Hospital\", 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']['PREDM', 'Page 3', 'Protocol Summary', 'PREDM: An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic', 'Adult Survivors of Childhood Cancer', 'Principal Investigator: Stephanie Dixon, MD, MPH', \"IND Holder: St. Jude Children's Research Hospital, # XXXX\", 'Brief Overview: This is a first-in survivor, single-arm pilot study with the goal of', 'establishing evidence of feasibility and safety of a combined pharmacologic (metformin)', 'and lifestyle intervention (using an existing digital platform) to prevent diabetes in', 'prediabetic adult survivors of childhood cancer. In addition, we will evaluate preliminary', 'data for efficacy of the combined intervention to improve measures of glycemic control,', 'insulin resistance, weight/anthropometric measures, physical activity and frailty. The', 'metformin + lifestyle intervention will be administered for 24 weeks and measures of', 'adherence, safety, glycemic control, insulin resistance and anthropometrics assessed. If', 'successful, this pilot will provide the preliminary evidence needed for a phase 2,', 'randomized controlled trial to establish efficacy. This proposal leverages the unique', 'resource of the SJLIFE cohort of extensively phenotyped survivors available for', 'longitudinal follow-up.', 'Intervention: 41 survivors age 18 to <45 years determined to have prediabetes based on', 'American Diabetes Association diagnostic criteria will be enrolled and receive the', 'combined metformin and lifestyle intervention (using a digitally delivered platform) for 6', 'months.', 'Brief Outline of Treatment Plan: Eligible subjects who meet inclusion criteria will', 'receive metformin extended release daily and be enrolled in the digital lifestyle', 'intervention program. Following a 2-week run-in period at lower dose (500 mg/day) to', 'minimize gastrointestinal side effects (diarrhea, nausea, flatulence, bloating), participants', 'will be escalated to a maximum dose of 1000 mg/day. The digitally delivered lifestyle', 'change program will include a core curriculum focused on diet quality, food types,', 'exercise and behavioral strategies for goal setting, and self-monitoring. The intervention', 'includes interaction with a lifestyle coach as well as a virtual peer group, hosted by a', 'second group coach. Study end points will include treatment adherence will be assessed by', 'telephone-based pill count at week 2, 4, 8, 16 and 20, and in-person assessment at', 'subsequent clinic visits (12 and 24 weeks). Adherence to the lifestyle program will be', 'monitored by completion logs from the digital platform as well as self-reported physical', 'activity (NHANES-PAQ) and accelerometer data. Safety will be assessed using the', 'Global Rating of Side Effects Burden, which includes the Common Terminology Criteria', 'for Adverse Events (CTCAE v5.0) grade. Glycemic control and insulin resistance will be', 'assessed by change from baseline in fasting plasma glucose (FPG), hemoglobin Alc', '(HbA1c), insulin resistance using the homestatic model assessment (HOMA-IR) and', 'insulin-like growth factor-binding protein 1 (IGF-BP1). We will also assess change from', 'baseline in weight, body fat percentage, waist circumference, physical activity (self-report', 'and accelerometer data) and frailty measures.', 'Study Design: Single-arm (combined metformin + digitally delivered lifestyle', 'intervention), open-label pilot intervention trial to determine: 1) feasibility and safety', 'using measures of treatment adherence, safety and adverse event reporting and 2)', 'preliminary evidence for efficacy using measures of glycemic control, insulin resistance,', \"St. Jude Children's Research Hospital\", 'Initial version, dated: 04-10-20', 'IRB approkB date', 'NUMBER: 20-0550', 'Protocol document date: 10-12-2020', 'IRB APPROVAL DATE: 11/10/2020']\n\n###\n\n", "completion": "END"}